수의 종양학 시장 : 동물 유형별, 치료법별, 암 유형별, 투여 방법별, 최종 사용자별 - 세계 시장 예측(2026-2032년)

The Veterinary Oncology Market is projected to grow by USD 4.74 billion at a CAGR of 14.47% by 2032.

Veterinary oncology has moved from a niche specialty into a core pillar of companion animal health care as pets live longer and owners pursue advanced cancer diagnostics and treatment. The American Veterinary Medical Association reports that approximately one in four dogs will develop neoplasia during life, and nearly half of dogs over age ten develop cancer, making early detection, staging, and evidence-based treatment increasingly important.

Growth in veterinary oncology is supported by pet humanization, expanding specialty hospitals, broader access to CT, MRI, ultrasound, cytology, histopathology, immunohistochemistry, flow cytometry, and molecular testing, and the availability of regulator-approved animal cancer therapies. Demand is strongest where referral networks, pet insurance, and board-certified oncology services improve affordability, continuity of care, and clinical decision-making for pet cancer treatment.

Transformative Shifts in the Veterinary Oncology Landscape

The veterinary oncology landscape is shifting from generalized chemotherapy toward multimodal, patient-specific care that combines surgery, radiation therapy, medical oncology, pain management, nutrition, and palliative support. Diagnostic quality is rising as cytology, biopsy, advanced imaging, flow cytometry, immunophenotyping, and molecular assays enable more accurate tumor classification, staging, prognosis, and treatment selection.

A second transformation is commercial and operational. Specialty hospitals are expanding referral capacity, general practitioners are using teleconsultation to triage complex cases, and owners increasingly evaluate treatment based on survival benefit, quality of life, adverse-event management, and transparent cost. These shifts favor providers that can integrate diagnostics, referral pathways, clinical protocols, clinical trial access, and compassionate communication.

Cumulative Impact of Artificial Intelligence on Veterinary Oncology

Artificial intelligence is beginning to affect veterinary oncology across imaging review, digital pathology, clinical documentation, workflow automation, and risk stratification. AI-enabled tools can help detect patterns in radiographs, ultrasound images, CT scans, histology slides, cytology images, and electronic medical records, supporting faster triage and more consistent follow-up for suspected pet cancer cases.

The cumulative impact is operational rather than fully autonomous: AI can reduce diagnostic delays, improve case prioritization, standardize reporting, support clinical decision support, and strengthen real-world evidence generation. However, adoption depends on veterinary-specific validation, explainable models, clinician oversight, data privacy, high-quality annotated datasets, and integration with laboratory information systems and hospital workflows.

Key Regional Insights Across Global Veterinary Oncology

North America remains the most mature regional environment for veterinary oncology, supported by high companion animal ownership, specialty referral networks, pet insurance adoption, advanced diagnostics, and access to board-certified oncologists, particularly in the United States and Canada. Europe follows with strong clinical standards across the European Union and established oncology services in the United Kingdom, Germany, France, Italy, and Spain, although reimbursement, medicine authorization, and referral access vary by country. Russia shows more concentrated development in major urban centers where advanced companion animal care infrastructure is available.

Asia-Pacific is expanding as urban pet ownership, premium veterinary clinics, and advanced diagnostics grow in China, Japan, Australia, South Korea, and India. Japan and Australia have well-established companion animal care systems, while China and India are building specialist capacity alongside rapid growth in urban veterinary services. Latin America is led by Brazil and Mexico, where companion animal populations, private veterinary investment, and diagnostic access are increasing. The Middle East, particularly GCC markets, is developing premium pet care infrastructure supported by high-income urban demand, while Africa remains earlier-stage, with growth concentrated in urban centers, veterinary schools, and private referral practices where pathology, imaging, and specialty surgery are accessible.

Key Group Insights for Veterinary Oncology Demand

Within major economic groups, the G7 anchors veterinary oncology innovation through advanced specialty care, pharmaceutical and diagnostic development, academic research, clinical training, pet insurance penetration, and stronger access to radiation oncology and advanced imaging. The European Union contributes harmonized regulatory oversight, cross-border clinical standards, pharmacovigilance requirements, and strong companion animal health infrastructure, making it central to evidence-based veterinary cancer care and responsible therapeutic adoption.

BRICS markets offer scale and long-term demand potential, especially in Brazil, China, and India, where pet populations, urban clinics, and private veterinary services are expanding, while specialist density remains uneven. ASEAN is gaining relevance through urbanization and premium pet care growth in markets such as Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines, with referral oncology emerging first in higher-income metropolitan areas. GCC countries are investing in high-end veterinary services, modern clinics, and companion animal diagnostics, while NATO countries collectively overlap with many of the world's strongest biomedical research, animal health, military working dog medicine, and specialty hospital ecosystems.

Key Country Insights in Companion Animal Cancer Care

The United States leads veterinary oncology through deep specialty hospital coverage, FDA-approved pet cancer therapies, advanced diagnostics, oncology residency training, and strong owner willingness to treat. Canada benefits from similar clinical standards and referral pathways, while Mexico and Brazil are expanding oncology access through urban private practices, diagnostic laboratories, and growing companion animal care spending. In Europe, the United Kingdom, Germany, France, Italy, and Spain support mature referral networks, professional oncology expertise, and access to surgery, imaging, chemotherapy, and palliative care, while Russia shows selective development in major cities where specialty services and advanced diagnostics are concentrated.

China and India represent high-potential veterinary oncology environments driven by rising pet ownership, urban clinics, premium pet care, and increasing diagnostic investment, though specialist availability and access to advanced therapies remain uneven. Japan has a sophisticated small animal veterinary sector with strong demand for minimally invasive diagnostics and quality-of-life-focused care. Australia benefits from established referral hospitals, veterinary schools, and advanced imaging access, while South Korea is supported by high urban pet ownership, modern clinics, and demand for specialized companion animal medicine. Across all countries, adoption is highest where general practitioners, diagnostic laboratories, surgeons, radiation centers, medical oncologists, and palliative care teams are connected through reliable referral pathways.

Actionable Recommendations for Veterinary Oncology Leaders

Industry leaders should prioritize integrated oncology pathways that connect primary veterinarians, diagnostic laboratories, imaging centers, surgeons, medical oncologists, radiation therapy providers, emergency teams, and palliative care specialists. Standardized staging protocols, tumor boards, survivorship plans, pain assessment tools, and owner education materials can improve treatment consistency, adherence, and trust.

Commercial strategies should focus on affordability, evidence, and access. Providers can expand through teleoncology, regional referral hubs, AI-assisted workflow tools, clinical trial partnerships, remote follow-up, and real-world outcomes registries. Manufacturers and service providers should invest in veterinary-specific indications, companion diagnostics, validated biomarkers, safety monitoring, pharmacovigilance, and post-authorization evidence to demonstrate measurable value for pets, owners, and clinicians.

Research Methodology for Veterinary Oncology Analysis

This executive summary is based on a structured review of verified public sources, including veterinary association guidance, regulatory databases, peer-reviewed veterinary oncology literature, animal health industry disclosures, clinical practice standards, academic publications, and regional pet care indicators. Emphasis is placed on data that can be corroborated through recognized veterinary, regulatory, academic, and industry sources, including disease burden evidence, approved therapeutic references, and professional specialty care standards.

The analysis applies market triangulation by comparing disease burden, pet ownership trends, specialty care availability, diagnostic adoption, regulatory approvals, clinical infrastructure, and regional veterinary service maturity. Qualitative insights are synthesized across demand drivers, technology adoption, competitive positioning, treatment access, and care delivery models to support decision-making in the veterinary oncology landscape without relying on market sizing, share estimates, or forecasts.

Conclusion: The Future of Veterinary Oncology

Veterinary oncology is entering a more data-driven and specialized phase as pet cancer diagnosis, treatment, and survivorship care become more accessible worldwide. Demand is reinforced by aging companion animals, owner willingness to pursue advanced care, and expanding clinical capabilities in diagnostics, surgery, radiation therapy, systemic therapy, immunotherapy, targeted treatment, pain control, and palliative medicine.

The next stage of development will depend on validated AI, stronger referral ecosystems, affordable treatment pathways, improved specialist training, and regionally appropriate service models. Organizations that combine clinical evidence, operational efficiency, compassionate communication, ethical care planning, and measurable outcomes will be best positioned in the global veterinary oncology landscape.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Veterinary Oncology Market, by Animal Type

• 7.1. Canine
• 7.2. Equine
• 7.3. Exotic Pets
  • 7.3.1. Aquatic Pets
  • 7.3.2. Birds
  • 7.3.3. Reptiles & Amphibians
• 7.4. Feline

8. Veterinary Oncology Market, by Treatment Mode

• 8.1. Chemotherapy
  • 8.1.1. Alkylating Agents
  • 8.1.2. Antimetabolites
  • 8.1.3. Cytotoxic Agents
  • 8.1.4. Vinca Alkaloids
• 8.2. Immunotherapy
  • 8.2.1. Cancer Vaccines
  • 8.2.2. Monoclonal Antibodies
• 8.3. Radiotherapy
  • 8.3.1. Brachytherapy
  • 8.3.2. External Beam Radiotherapy
• 8.4. Surgery
• 8.5. Targeted Therapy

9. Veterinary Oncology Market, by Cancer Type

• 9.1. Hemangiosarcoma
• 9.2. Lymphoma
• 9.3. Mammary Carcinoma
• 9.4. Mast Cell Tumors
• 9.5. Osteosarcoma

10. Veterinary Oncology Market, by Mode of Administration

• 10.1. Intravenous (IV)
• 10.2. Oral
• 10.3. Topical

11. Veterinary Oncology Market, by End User

• 11.1. Academic Institutions
• 11.2. Veterinary Hospitals & Clinics

12. Veterinary Oncology Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Veterinary Oncology Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Veterinary Oncology Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. AB Science SA
• 16.2. Anivive Lifesciences
• 16.3. Ardent Animal Health, LLC
• 16.4. Boehringer Ingelheim International GmbH
• 16.5. Ceva Sante Animale S.A.
• 16.6. Covetrus, Inc.
• 16.7. Elanco Animal Health Incorporated
• 16.8. ELIAS Animal Health
• 16.9. Fidocure
• 16.10. IDEXX Laboratories, Inc.
• 16.11. Karyopharm Therapeutics Inc.
• 16.12. Leroy Biotech S.A.S.
• 16.13. Merck KGaA,
• 16.14. Morphogenesis, Inc.
• 16.15. Nippon Zenyaku Kogyo Co., Ltd.
• 16.16. PetCure Oncology LLC
• 16.17. PharmAust Limited
• 16.18. Rhizen Pharmaceuticals AG
• 16.19. Torigen Pharmaceuticals Inc.
• 16.20. Varian Medical Systems, Inc.
• 16.21. Vetco Pharmaceuticals Inc.
• 16.22. VetDC, Inc.
• 16.23. Virbac SA
• 16.24. VolitionRx Limited
• 16.25. Zoetis Inc.